Although TLR9 is mostly associated with tumor promotion, recent findings show that treatment with synthetic agonist CpG-1668 suppresses prostate tumor growth by enhancing systemic innate immunity, marked by increased macrophages, CD8+ T cells, and neutrophils, and inducing macrophage-derived IFN-β that inhibits cancer cell proliferation (22). Here, CD8A is linked to neoplasm.